Captor Therapeutics Spolka Akcyjna
CTX.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | PLN 0 | PLN 2 | PLN 3 | PLN 3 |
| % Growth | -100% | -22.9% | -11.8% | – |
| Cost of Goods Sold | -PLN 2 | PLN 3 | PLN 1 | PLN 2 |
| Gross Profit | PLN 2 | -PLN 1 | PLN 2 | PLN 1 |
| % Margin | – | -29% | 66.5% | 27.3% |
| R&D Expenses | PLN 12 | PLN 10 | PLN 11 | PLN 8 |
| G&A Expenses | PLN 1 | PLN 4 | PLN 3 | PLN 3 |
| SG&A Expenses | PLN 1 | PLN 4 | PLN 3 | PLN 2 |
| Sales & Mktg Exp. | PLN 0 | PLN 0 | PLN 0 | -PLN 2 |
| Other Operating Expenses | PLN 1 | -PLN 4 | -PLN 1 | PLN 3 |
| Operating Expenses | PLN 14 | PLN 10 | PLN 12 | PLN 12 |
| Operating Income | -PLN 12 | -PLN 11 | -PLN 11 | -PLN 11 |
| % Margin | – | -534.6% | -411.2% | -371.7% |
| Other Income/Exp. Net | PLN 0 | PLN 1 | -PLN 0 | PLN 0 |
| Pre-Tax Income | -PLN 11 | -PLN 10 | -PLN 11 | -PLN 9 |
| Tax Expense | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Net Income | -PLN 11 | -PLN 10 | -PLN 11 | -PLN 9 |
| % Margin | – | -485.3% | -411.3% | -296.5% |
| EPS | -2.08 | -1.77 | -1.95 | -1.59 |
| % Growth | -17.5% | 9.2% | -22.6% | – |
| EPS Diluted | -2.08 | -1.77 | -1.95 | -1.59 |
| Weighted Avg Shares Out | 6 | 6 | 5 | 5 |
| Weighted Avg Shares Out Dil | 6 | 6 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 0 | PLN 1 | PLN 0 | PLN 0 |
| Interest Expense | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Depreciation & Amortization | PLN 1 | PLN 1 | PLN 1 | PLN 1 |
| EBITDA | -PLN 10 | -PLN 9 | -PLN 9 | -PLN 8 |
| % Margin | – | -469.3% | -360.3% | -254.3% |